Corcept Therapeutics
CORT
189 hedge funds and large institutions have $1.43B invested in Corcept Therapeutics in 2017 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 65 increasing their positions, 46 reducing their positions, and 13 closing their positions.
262% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 13
139% more call options, than puts
Call options by funds: $11.7M | Put options by funds: $4.89M
73% more capital invested
Capital invested by funds: $824M → $1.43B (+$605M)
41% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 46
21% more funds holding
Funds holding: 156 → 189 (+33)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
3.67% more ownership
Funds ownership: 61.7% → 65.37% (+3.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$26.8M |
| 2 |
Renaissance Technologies
New York
|
+$14.7M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$9.23M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$8.89M |
| 5 |
AAM
AMI Asset Management
Los Angeles,
California
|
+$7.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$33.2M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$28.7M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$10.4M |
| 4 |
ISL
Ingalls & Snyder LLC
New York
|
-$6.46M |
| 5 |
Morgan Stanley
New York
|
-$6.27M |
CORT Hedge Fund Activity: Q3 2017 in Review
189 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q3 2017, worth a combined $1.43B — up 73% from $824M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new CORT positions and 13 closed out — a net gain of 34 holders — while 65 added to existing stakes and 46 trimmed.
The largest buyer was Vanguard Group, adding an estimated $26.8M. The largest seller was Federated Hermes, cutting an estimated $33.2M.
- 189 institutional investors held Corcept Therapeutics (CORT) as of Q3 2017, up from 156 in Q2 2017.
- Funds reported $1.43B of Corcept Therapeutics stock for Q3 2017, up 73% quarter-over-quarter.
- 47 funds opened new Corcept Therapeutics positions in Q3 2017 and 13 closed out, a net change of +34 holders.
- The largest Corcept Therapeutics buyer in Q3 2017 was Vanguard Group, an estimated $26.8M added.
- The largest Corcept Therapeutics seller in Q3 2017 was Federated Hermes, an estimated $33.2M sold.
Based on aggregated 13F filings for Q3 2017.